Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NNMT | P40261 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29858015 | 1.00 | CTSA (0.44) | CTSAALDH1A1APLNRTDP1POLB | |
| SCHEMBL8866132 | 0.86 | CTSA (0.45) | CTSAALDH1A1APLNRTDP1POLB | |
| SCHEMBL29527015 | 0.84 | TDP1 (0.61) | CTSAAPLNRTDP1POLBKDM4E | |
| SCHEMBL17338 | 0.84 | TDP1 (0.61) | CTSAAPLNRTDP1POLBKDM4E | |
| SCHEMBL2304053 | 0.82 | NNMT (0.56) | CTSAAPLNRTDP1POLBKDM4E | |
| SCHEMBL875715 | 0.82 | MAPT (0.55) | CTSAALDH1A1APLNRKDM4EMEN1 | |
| SCHEMBL31264286 | 0.82 | MAPT (0.55) | CTSAALDH1A1APLNRKDM4EMEN1 | |
| SCHEMBL15019936 | 0.82 | KDM4E (0.44) | CTSAAPLNRTDP1POLBKDM4E | |
| SCHEMBL2277413 | 0.82 | TDP1 (0.59) | CTSAAPLNRTDP1POLBKDM4E | |
| Hydrochloric Acid SCHEMBL29133272 | 0.82 | TDP1 (0.59) | CTSAAPLNRTDP1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116540465-B | Electrochromic ion storage layer film and preparation method thereof | NINGBO MI RUO ELECTRONIC TECHNOLOGY Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-116540465-A | Novel electrochromic ion storage layer film and preparation method thereof | 宁波祢若电子科技有限公司 | 2023-08-04 | — | — | CN | claimed |
| CN-104357504-A | Cell catalysis for producing chirality methoxyl pyridine ethanol | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2015-02-18 | — | — | CN | claimed |
| WO-2013006000-A2 | METHOD FOR DETECTING BREAST CANCER USING RESPIRATORY GAS | 주식회사 알앤엘내츄럴 (KR) | 2013-01-10 | — | — | WO | claimed |
| CN-116540465-B | Electrochromic ion storage layer film and preparation method thereof | NINGBO MI RUO ELECTRONIC TECHNOLOGY Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-121471279-A | Bidentate cobalt complex containing imidazo [1, 2-alpha ] pyridine group and preparation method and application thereof | 郑州大学 | 2026-02-06 | — | — | CN | disclosed |
| US-20250243177-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| CN-116987047-A | Heterocyclic oxime compound, preparation method, application and composition thereof | 贵州大学 | 2023-11-03 | — | — | CN | disclosed |
| WO-2023208986-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-11-02 | — | — | WO | disclosed |
| CN-116540465-A | Novel electrochromic ion storage layer film and preparation method thereof | 宁波祢若电子科技有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| WO-2009103879-A1 | NOVEL NITROGEN-CONTAINING ORGANIC COMPOUNDS THAT CAN BE USED AS PRECURSOR OF A CATALYTIC COMPOSITION | IFP (FR) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009103879-A1 | NOVEL NITROGEN-CONTAINING ORGANIC COMPOUNDS THAT CAN BE USED AS PRECURSOR OF A CATALYTIC COMPOSITION | IFP (FR) | 2009-08-27 | — | — | WO | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | CTSA 949/4885ALDH1A1 139/4885APLNR 4609/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | CTSA 1631/4885ALDH1A1 3841/4885APLNR 3263/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | CTSA 2388/4885ALDH1A1 2843/4885APLNR 390/4885 |
| US-20250243177-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | CTSA 3079/4885ALDH1A1 1325/4885APLNR 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.